Warfarin Dosing Calculator
Estimate the warfarin maintenance dose with the validated Gage clinical algorithm (Clinical Pharmacology and Therapeutics 2008): age, height, weight, race, enzyme inducers and amiodarone predict the weekly dose.
Enter age, height, weight, race, smoking or enzyme inducer use and amiodarone use to estimate the weekly warfarin maintenance dose in milligrams, with a suggested daily equivalent. This is a starting estimate only: all ongoing dosing is titrated against the INR.
Why warfarin dosing needs a calculator
Warfarin is famously difficult to dose. The stable maintenance dose varies more than tenfold between patients, from under 1 mg to over 10 mg daily, driven by age, body size, diet, interacting drugs, comorbidities and genetics. Too little leaves the patient unprotected against stroke or recurrent thrombosis; too much risks major bleeding. Traditional initiation with a fixed 5 mg daily dose therefore overshoots in some patients and undershoots in others, and several days of INR chasing follow before stability is reached.
Dose prediction algorithms compress that learning period. The Gage clinical algorithm, the most widely validated of the non-genetic models, was derived from a diverse cohort and predicts the square root of the weekly dose with a validated R-squared around 0.5, meaning it explains about half of the inter-patient variability. That is far from perfect, but it is substantially better than a fixed starting dose, and it is available immediately, without waiting for genotype results that most centres cannot produce at the bedside.
The variables and what they do
Age enters the model in decades with a negative coefficient: each decade of life reduces the predicted dose, reflecting slower clearance and greater sensitivity in older patients. Height and weight enter positively, since larger bodies distribute and clear more drug. Race modifies the prediction in both directions: Asian ancestry lowers the predicted dose, Black ancestry raises it, consistent with population differences in warfarin sensitivity partly mediated by VKORC1 haplotypes.
The two drug variables capture the most important interactions. Enzyme inducers, typified by smoking and drugs such as carbamazepine and rifampicin, accelerate warfarin clearance and raise the required dose substantially. Amiodarone does the opposite, inhibiting CYP2C9 and CYP1A2 and lowering the dose needed; starting or stopping amiodarone in a patient established on warfarin is one of the commonest causes of INR excursions in practice. The model does not include diet, alcohol, interacting antibiotics, or thyroid status, all of which the clinician must layer on top.
How to use the estimate
Treat the output as a starting maintenance dose, not a prescription. Convert the weekly milligrams into a practical daily regimen using available tablet strengths, then monitor the INR frequently during initiation, typically every few days, adjusting toward the target range, usually 2.0 to 3.0. The algorithm's prediction is most valuable in the first week, when it reduces the overshoot and undershoot of fixed dosing; within a few INR results, the INR itself becomes the far better guide and the prediction has served its purpose.
Several situations call for extra caution around the estimate. Very elderly or frail patients, those with liver disease, heart failure, or poor nutrition, and patients starting interacting drugs may need lower doses than predicted. Conversely, the estimate assumes average vitamin K intake; major dietary changes can shift requirements. When the INR proves unstable despite reasonable dosing, poor adherence, undeclared interacting substances, or hypermetabolic states should be investigated before the algorithm is blamed.
Warfarin versus direct oral anticoagulants
The choice of anticoagulant precedes any dosing calculation. Direct oral anticoagulants are preferred for most patients with non-valvular atrial fibrillation and for treatment of venous thromboembolism, because of their predictable effect, fewer interactions and lower intracranial bleeding risk. Warfarin remains mandatory in mechanical heart valves and moderate to severe mitral stenosis, where direct agents are ineffective or harmful, and it remains useful in severe renal impairment, antiphospholipid syndrome with arterial events, and where cost or monitoring infrastructure favours it. This calculator is for patients in whom warfarin has already been chosen.
Limitations
The Gage algorithm explains about half of dose variability, which means half remains unexplained: diet, adherence, interacting drugs, illness and genetics all move the true requirement. It was derived in adults and should not be extrapolated to children. It does not account for the loading phase, for bridging, or for perioperative management, which follow separate protocols. Genetic variants in CYP2C9 and VKORC1 are the largest single source of unexplained variability; where rapid genotyping is available, pharmacogenetic algorithms perform better. Above all, the estimate never replaces INR monitoring, and any dosing decision must be made or confirmed by the treating clinician.
References
- Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;83(3):511-526.
- International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753-764.
- January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 guideline for the management of patients with atrial fibrillation. Circulation. 2019;140(2):e125-e151.
Key takeaways
- The Gage clinical algorithm predicts the square root of the weekly warfarin dose from age, height, weight, race, enzyme inducer use and amiodarone use.
- Older age, Asian ancestry and amiodarone lower the predicted dose; larger body size, Black ancestry and enzyme inducers raise it.
- The output is a starting maintenance estimate only; all ongoing dosing is titrated against the INR, usually targeting 2.0 to 3.0.
- Starting or stopping amiodarone in a warfarinised patient requires pre-emptive dose adjustment and closer INR monitoring.
- Direct oral anticoagulants are preferred for most non-valvular atrial fibrillation; warfarin remains required for mechanical valves and moderate to severe mitral stenosis.
- The algorithm explains about half of dose variability; diet, adherence, interacting drugs and genetics account for the rest.
Frequently asked questions
How is the starting warfarin dose estimated?
This calculator implements the validated Gage clinical algorithm, which predicts the square root of the weekly warfarin dose from age in decades, height in centimetres, weight in kilograms, Asian or Black race, use of enzyme inducers such as smoking, and amiodarone use. The predicted weekly dose is then divided into a practical daily regimen and titrated against the INR, which remains the definitive guide to dosing.
Does the calculator replace INR monitoring?
No. The algorithm estimates a starting maintenance dose only; all subsequent dosing is driven by INR results. Warfarin has a narrow therapeutic index and wide inter-individual variability, so INR monitoring, typically targeting 2.0 to 3.0 for most indications, is mandatory and no prediction algorithm changes that.
Why does amiodarone lower the warfarin dose?
Amiodarone inhibits the cytochrome P450 enzymes, principally CYP2C9 and CYP1A2, that clear the active S-enantiomer of warfarin, so the same warfarin dose produces a higher INR. The Gage algorithm subtracts a fixed term for amiodarone use, and in practice starting or stopping amiodarone in a warfarinised patient calls for pre-emptive dose adjustment with closer INR checks.
What about pharmacogenetic warfarin dosing?
Genetic variants in CYP2C9 and VKORC1 explain a large share of warfarin dose variability, and pharmacogenetic algorithms incorporating them outperform clinical algorithms. However, genotype is rarely available at initiation, and trials of genotype-guided dosing have shown mixed clinical benefit. The clinical algorithm here is the practical choice when genotype is unknown, which is the usual situation.
Which patients should not start warfarin based on this estimate?
The estimate is a starting point, not a treatment decision. Warfarin is contraindicated in pregnancy, and direct oral anticoagulants are preferred over warfarin for most non-valvular atrial fibrillation. Warfarin remains required in mechanical heart valves and moderate to severe mitral stenosis. The decision to anticoagulate, and with which agent, belongs to the treating clinician.
How should the weekly dose be divided into daily tablets?
Divide the weekly total into seven daily doses as evenly as tablet strengths allow, for example 4 mg daily for 28 mg per week, or alternating 4 mg and 5 mg for 31.5 mg per week. Keep the regimen simple enough for adherence, and recheck the INR within a few days of any change.